| 영문 | medical record | 한글 | 의무기록 |
|---|---|---|---|
| 설명 | 의무기록은 법적으로 보호를 받게 되어 있으며, 특히 진료기록부와 수술기록부는 10년간 보존을 하도록 법에 명시되어 있다. 또한 법에 의한 경우가 아니고서는 타인에게 보여지지 않도록 되어 있다. 그러나, 환자의 진료를 위하여, 다른 의사의 요구가 있으면, 이를 보여주도록 되어 있다. |
||
| 영문 | medical examination | 한글 | 의학적 검사 |
|---|---|---|---|
| 설명 | 1. 건강의 유지와 증진, 병의 조기 발견이나 예방 따위를 위해서 심신의 상태를 검사하는 일. 2. 의사나 치과의사가 자각적-타각적으로 건강한 사람에 대하여 그 건강 상태를 진찰하는 일. 건강을 유지하기 위해서는 질병의 진단과 치료가 필요하지만, 치료에 있어서도 자각증상이나 타각증상이 있고 나서 손을 쓰다 보면 이미 때가 늦을 경우가 많으므로, 발병 초기에 조기진단을 함으로써 건강생활을 적극적으로 설계하려는 데에 의의가 있는 것이다. 건강진단을 크게 나누면, 개인적 건강유지를 위한 것과, 국민 전체의 건강유지를 위하여 행정적으로 특정한 대상자에게 의무적으로 하는 것이 있는데, 후자의 경우를 ‘정기건강진단’이라고 한다. 근로보건관리규정에는 위생상 유해한 직장의 종업원은 연2회 이상의 건강진단을 필요로 하고 있으며, 그 밖의 직장에서는 연1회 이상으로 규정하고 있다. 학교보건법에서는 매년 학생과 교직원의 신체검사를 하게 되어 있고, 결핵예방법에서는 모든 국민은 연1회 이상 결핵에 관한 건강진단을 받도록 되어 있으며, 모자보건법에서는 임신부와 영유아에 대한 건강진단을 규정하고 있다. 이 밖에 접객업소에서도 전염병-피부병에 관한 건강진단을 받아야 한다는 규정이 업종별로 정해져 있다. |
||
| 영문 | electronic medical record(EMR) | 한글 | 전자의무기록 |
|---|---|---|---|
| 설명 | 의사가 종이 대신 컴퓨터에 직접 환자의 임상정보를 입력하면 이를 데이터베이스화하여 새로운 정보로 가공-생성하는 의료정보시스템. 환자의 진료기록을 찾아 진료실에 전달하고 다시 처방전을 받아 조제하는 일련의 과정이 네트워크로 처리돼 환자대기시간이 대폭 줄고, 별도의 진료기록실이 불필요하다. |
||
| FDP(s) | 1) Fibrinolytic split Products(= FSP) 2) Fibrinogen Degradation Products |
|---|---|
| FSP | familial spastic paraplegia; fibrin split products; fibrinogen split products; fine suspended partic... |
| MPS | 1) Mononuclear Phagocyte System 2) Mucopolysaccharidosis; Muco 다당류 축적 질환... |
| MPS | meconium plug syndrome; medial premotor system; Member of the Pharmaceutical Society; microbial prof... |
| MS | Maffuci syndrome; maladjustment score; mandibular series; Marfan syndrome; Marie-Strumpell [syndrome... |
| MPS | Methylprednisolone |
|---|---|
| MPS | Mononuclear Phagocyte System |
| MPS | Mononuclear-Phagocytic-System |
| MPS | Mucopolysaccharide |
| MPS | Mucopolysaccharidoses |
| biological products | Complex pharmaceutical substances, preparations, or agents of organic origin, usually obtained by biological methods or assay, that depend for their action on the processes affecting immunity. They are used especially in diagnosis and treatment of disease (as vaccines or pollen extracts). Biological products are differentiated from biological factors in that the latter are compounds with biological or physiological activity made by living organisms. (12 Dec 1998) |
|---|---|
| blood products | Biopharmaceutical products purified from human blood, such as the blood clotting factor VIII used to treat haemophiliacs. (Recombinant factor VIII is also on the market.) The term also refers to biopharmaceuticals that act on blood or the cells that make blood. These products are often produced by the cells themselves, but in such tiny amounts that extracting them from blood is impractical, and so they are genetically engineered. (14 Nov 1997) |
| gene products, env | Retroviral proteins, often glycosylated, coded by the envelope (env) gene. They are usually synthesised as protein precursors (polyproteins) and later cleaved into the final products by a viral protease. (12 Dec 1998) |
| gene products, gag | Proteins coded by the retroviral gag gene. The products are usually synthesised as protein precursors or polyproteins, which are then cleaved by viral proteases to yield the final products. Many of the final products are associated with the nucleoprotein core of the virion. Gag is short for group-specific antigen. (12 Dec 1998) |
| gene products, nef | Products of the HIV nef gene (formerly 3'-orf gene). The products trans-suppress viral replication and function as negative regulators of transcription. Nef stands for negative factor. (12 Dec 1998) |
| gene products, pol | Retroviral proteins coded by the pol gene. Often synthesised as a gag-pol fusion protein (fusion proteins, gag-pol) and later cleaved into final products that include reverse transcriptase, endonuclease/integrase, and viral protease. Pol is short for polymerase, the enzyme class of reverse transcriptase. (12 Dec 1998) |
| gene products, rev | Trans-acting nuclear proteins whose functional expression are required for HIV viral replication. Specifically, the rev gene products are required for processing and translation of the HIV gag and env mRNAs, and thus rev regulates the expression of the viral structural proteins. Rev can also regulate viral regulatory proteins. A cis-acting antirepression sequence (car) in env, also known as the rev-responsive element (rre), is responsive to the rev gene product. Rev is short for regulator of virion. (12 Dec 1998) |
| gene products, rex | Post-transcriptional regulatory proteins required for the accumulation of mRNAs that encode the gag and env gene products in HTLV-I and HTLV-II. The rex (regulator x; x is undefined) products act by binding to elements in the ltr. (12 Dec 1998) |
| gene products, tat | Trans-acting transcription factors. Nuclear proteins whose expression is required for HIV viral replication. The tat protein stimulates HIV-ltr-driven RNA synthesis for both viral regulatory and viral structural proteins. Tat stands for trans-activation of transcription. (12 Dec 1998) |
| gene products, tax | Transcriptional trans-acting proteins of the promoter elements found in the long-terminal repeats (ltr) of HTLV-I and HTLV-II. The tax (trans-activator x; x is undefined) proteins act by binding to enhancer elements in the ltr. (12 Dec 1998) |
| gene products, vif | A 23 kD regulatory protein important for virion infectivity in HIV. The protein is found in the cytoplasm of HIV-infected cells and is not absolutely required for virion formation. (12 Dec 1998) |
| gene products, vpr | Trans-acting proteins which accelerate virus replication in HIV. The vpr proteins act in trans to increase the levels of HIV specified proteins. Vpr is short for viral protein r, where r is undefined. (12 Dec 1998) |
| gene products, vpu | Non-glycosylated, membrane-associated, 16 kD proteins which are expressed in large amounts in cells infected with HIV-1. The proteins are required for efficient virion maturation and release. They are not present in HIV-2 nor in siv. Vpu is short for viral protein u, with u undefined. (12 Dec 1998) |
| meat products | Articles of food which are derived by a process of manufacture from any portion of carcasses of any animal used for food (e.g., head cheese, sausage, scrapple). (12 Dec 1998) |
| glycosylation end products, advanced | Products derived from the nonenzymatic reaction of glucose and proteins in vivo that exhibit a yellow-brown pigmentation and an ability to participate in protein-protein cross-linking. These substances are involved in biological processes relating to protein turnover and it is believed that their excessive accumulation contributes to the chronic complications of diabetes mellitus. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|